Biso Api Structure (Api Pic New1)
Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-1769
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 71335-1769). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Hctz Api Structure (Api Pic New2)
Label (Lbl713351769)
This appears to be a label of medication named Bisoprolol Fumarate/Hctz 5/6.25 Tablet for oral consumption. It is manufactured by Edenbridge Pharmaceuticals LLC and is meant to be kept at room temperature. The label also contains instructions on safely storing the medicine and keeping it out of reach of children. The medicine comes in a container with 30 tablets, and the label includes the NDC (National Drug Code) number and the expiration date.*
Table 1 (Table 1 New)
The text provides data on Sitting Systolic/Diastolic Pressure (BP) and Heart Rate (HR) before and after the treatment for two studies. The first study compares the placebo and BSH6.25, and the second study compares Placebo, H625mg, B3/H62smg, and BI0/H625. The data shows the mean decrease in BP and increase or decrease in heart rate after 3.4 weeks of treatment. The text also gives information on drug effects, and observed mean change from baseline minus placebo.*
Table-3 (Table 3 New)
This is a table of the percentage of patients who experienced adverse events during a drug trial. The table lists adverse experiences by body system and shows the percentage for each experience and whether it was drug-related. Adverse experiences were reported for the cardiovascular, respiratory, body as a whole, central nervous system, musculoskeletal, psychiatric, and gastrointestinal body systems. The adverse experiences included in the table were bradycardia, arrhythmia, peripheral ischemia, chest pain, bronchospasm, cough, tinnitus, and insomnia, among others.*
Table-2 (Table New 2)
The available text is showing a table of serum potassium data from US, which seems to be placebo-controlled. It includes mean change in potassium levels measured in mEq/L in the year 2004. It also displays the percentage of patients with hypokalemia. No further information is available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
